Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 30, 2022 - Issue 6
Submit an article Journal homepage
208
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Subconjunctival Rituximab Administration for the Treatment of Scleritis

D. P. C. Vergouwena Department of Ophthalmology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands;b Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The NetherlandsCorrespondence[email protected]
View further author information
,
J. C. Ten Bergea Department of Ophthalmology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The NetherlandsView further author information
,
N. C. Naus-Postemaa Department of Ophthalmology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The NetherlandsView further author information
&
A. Rothovaa Department of Ophthalmology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The NetherlandsView further author information
Pages 1309-1311 | Received 18 Jun 2021, Accepted 09 Nov 2021, Published online: 16 Feb 2022

References

  • Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P. Scleritis: immunopathogenesis and molecular basis for therapy. Prog Retinal Eye Res. 2013;35:44–62. doi:10.1016/j.preteyeres.2013.02.004.
  • Wieringa WG, Wieringa JE, ten Dam-van Loon NH, Los LI. Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology. 2013;120(2):379–386. doi:10.1016/j.ophtha.2012.08.005.
  • Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121(10):1885–1891. doi:10.1016/j.ophtha.2014.04.044.
  • Cao JH, Oray M, Cocho L, Foster CS. Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol. 2016;164:22–28. doi:10.1016/j.ajo.2015.12.032.
  • You C, Ma L, Lasave AF, Foster CS. Rituximab induction and maintenance treatment in patients with scleritis and granulomatosis with polyangiitis (Wegener’s). Ocul Immunol Inflamm. 2018;26(8):1166–1173. doi:10.1080/09273948.2017.1327602.
  • Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res. 2019;61(1):44–50. doi:10.1159/000486791.
  • Ng CC, Sy A, Cunningham ET Jr. Rituximab for non-infectious uveitis and scleritis. J Ophthalmic Inflamm Infect. 2021;11(1):23. doi:10.1186/s12348-021-00252-4.
  • Sohn EH, Wang R, Read R, et al. Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Ophthalmology. 2011;118(10):1932–1937. doi:10.1016/j.ophtha.2011.02.043.
  • Dutta Majumder P, Agrawal R, McCluskey P, Biswas J. Current approach for the diagnosis and management of noninfective scleritis. Asia Pac J Ophthalmol (Phila). 2020;10:212–223. doi:10.1097/APO.0000000000000341.
  • Johnson KS, Chu DS. Evaluation of sub-tenon triamcinolone acetonide injections in the treatment of scleritis. Am J Ophthalmol. 2010;149(1):77–81. doi:10.1016/j.ajo.2009.07.035.
  • Savino G, Battendieri R, Gari M, Caputo CG, Laurenti L, Blasi MA. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. J Cancer Res Clin Oncol. 2013;139(7):1251–1255. doi:10.1007/s00432-013-1438-9.
  • Savino G, Battendieri R, Siniscalco A, et al. Intraorbital injection of rituximab in idiopathic orbital inflammatory syndrome: case reports. Rheumatol Int. 2015;35(1):183–188. doi:10.1007/s00296-014-3054-7.
  • Demirci H, Kauh CY, Rajaii F, Elner VM. Intralesional rituximab for the treatment of recurrent ocular adnexal lymphoma. Ophthalmic Plast Reconstr Surg. 2017;33(3SSuppl 1):S70–S71. doi:10.1097/IOP.0000000000000666.
  • Ng CC, Sy A, Cunningham ET Jr. Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease. J Ophthalmic Inflamm Infect. 2021;11(1):24. doi:10.1186/s12348-021-00253-3.
  • Laurenti L, De Padua L, Battendieri R, et al. Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation. Leuk Res. 2011;35(5):682–684. doi:10.1016/j.leukres.2011.01.030.
  • Ferreri AJ, Govi S, Colucci A, Crocchiolo R, Modorati G. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. Ophthalmology. 2011;118(1):24–28. doi:10.1016/j.ophtha.2010.04.036.
  • Kvopka M, Lake SR, Smith JR. Intraocular chemotherapy for vitreoretinal lymphoma: a review. Clin Exp Ophthalmol. 2020;48(2):240–248. doi:10.1111/ceo.13668.
  • Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LL. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood. 2006;108(5):1451–1460. doi:10.1182/blood-2006-02-005017.
  • Olsen TG, Heegaard S. Orbital lymphoma. Surv Ophthalmol. 2019;64(1):45–66. doi:10.1016/j.survophthal.2018.08.002.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.